A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.

NCT04903093 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: Abrocitinib tablet
DRUG: Abrocitinib Suspension F1
DRUG: Abrocitinib Suspension F2
DRUG: Abrocitinib Suspension F3
DRUG: Abrocitinib Suspension F4
DRUG: Abrocitinib Suspension F5
DRUG: Abrocitinib Suspension F6
DRUG: Famotidine

Sponsor

Pfizer